NASDAQ:MTCR Metacrine (MTCR) Stock Price, News & Analysis → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free MTCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.58▼$0.5950-Day Range$0.55▼$0.5952-Week Range$0.30▼$0.59Volume83,889 shsAverage Volume225,834 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Metacrine alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Metacrine Stock (NASDAQ:MTCR)Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him MTCR Stock News HeadlinesApril 17, 2024 | reuters.comUS says China is boosting Russia's war machine in UkraineDecember 20, 2023 | bbc.comTwitter says hackers downloaded private account dataMay 1, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. November 9, 2023 | morningstar.comAN2 Therapeutics Inc ANTXJuly 8, 2023 | morningstar.comBeijing Huafeng Test & Control Technology Co Ltd Class AJuly 3, 2023 | nbcnews.com3 children among 9 dead as Russian missile slams into pizza restaurantMarch 31, 2023 | abcnews.go.comGun ControlMarch 21, 2023 | usnews.comGun Control And Gun RightsMay 1, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. March 20, 2023 | nbcnews.comMajor Russian missile barrage slams targets across UkraineMarch 15, 2023 | bbc.co.ukDnipro missile: Son in search of his motherMarch 9, 2023 | thestreet.comHow Elon Musk Controls Tesla With Only a Minority Ownership StakeFebruary 24, 2023 | forbes.comOld Tax Regime Vs. New Tax Regime: Which Is Better In 2023?December 23, 2022 | finance.yahoo.comMetacrine and Equillium Mutually Agree to Terminate Definitive Merger AgreementNovember 17, 2022 | finanznachrichten.deMetacrine, Inc.: Metacrine Reports Third-Quarter 2022 ResultsNovember 15, 2022 | finance.yahoo.comMetacrine Reports Third-Quarter 2022 ResultsOctober 11, 2022 | marketscreener.comMETACRINE, INC. : Other Events (form 8-K) - Marketscreener.comSeptember 28, 2022 | finance.yahoo.comEquillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis - Yahoo FinanceSeptember 25, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of TALO, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - BenzingaSeptember 22, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - BenzingaSeptember 21, 2022 | marketwatch.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - MarketWatchSeptember 19, 2022 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR - PR NewswireSeptember 17, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equillium (NASDAQ:EQ) - BenzingaSeptember 8, 2022 | benzinga.comMETACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCRSeptember 7, 2022 | globenewswire.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR - GlobeNewswireSeptember 7, 2022 | benzinga.comApexigen, Inc. - Common Stock (APGN), (AQST), (ATIP), (ATXI), Cardiff Oncology, Inc. - Common Stock (CRDF - BenzingaSeptember 7, 2022 | finance.yahoo.comEquillium to Acquire Metacrine in All-Stock Transaction - Yahoo FinanceSee More Headlines Receive MTCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2021Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTCR CUSIPN/A CIK1634379 Webwww.metacrine.com Phone858-369-7800FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-59.33% Debt Debt-to-Equity Ratio0.34 Current Ratio12.15 Quick Ratio12.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.43Miscellaneous Outstanding Shares42,570,000Free Float36,695,000Market Cap$24.75 million OptionableNot Optionable Beta-0.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. David M. Maggio (Age 64)Chief Bus. Officer, Pres, CEO, Sec., Treasurer, Principal Financial & Acct. Officer Key CompetitorsLipocineNASDAQ:LPCNBullfrog AINASDAQ:BFRGIterum TherapeuticsNASDAQ:ITRMSensei BiotherapeuticsNASDAQ:SNSENRx PharmaceuticalsNASDAQ:NRXPView All Competitors MTCR Stock Analysis - Frequently Asked Questions How were Metacrine's earnings last quarter? Metacrine, Inc. (NASDAQ:MTCR) announced its quarterly earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.06. What other stocks do shareholders of Metacrine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Metacrine investors own include Bridgewater Bancshares (BWB), Bank of Commerce (BOCH), Blink Charging (BLNK), Bloomin' Brands (BLMN), Bausch Health Companies (BHC), Bridge Bancorp (BDGE), Bank of America (BAC), AXIS Capital (AXS), Avadel Pharmaceuticals (AVDL) and Blue Apron (APRN). When did Metacrine IPO? Metacrine (MTCR) raised $84 million in an IPO on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. This page (NASDAQ:MTCR) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportYour bank is lying to you.MyBankTrackerThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPub#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
